GSK plc has announced a pivotal moment in its oncology efforts with the FDA's recent accelerated approval of Nelkarmi (neladalkib) for the treatment of adults with advanced ALK-positive non-small cell lung cancer (NSCLC). This approval is significant as it expands GSK's oncology portfolio and provides a new treatment option for patients who have previously received other therapies.

The approval of Nelkarmi is based on promising results from the phase I/II ALKOVE-1 trial, which demonstrated clinically meaningful responses in patients with advanced ALK-positive NSCLC. According to GSK, the drug is designed to address key challenges associated with this type of cancer, including treatment resistance and the ability to penetrate the blood-brain barrier.

Background

GSK plc, incorporated in England and Wales, is a global biopharmaceutical company focused on developing innovative medicines. The company operates in the pharmaceutical preparations sector, specifically targeting areas such as oncology, vaccines, and respiratory diseases. GSK is listed on the New York Stock Exchange under the ticker symbol GSK and also trades on the OTC market as GLAXF. Recent filings include a series of 6-K forms, with the latest dated November 18, 2026, detailing this significant FDA approval.

What the Filing Says

The recent filing highlights that the FDA granted accelerated approval for Nelkarmi based on its performance in the ALKOVE-1 trial. The trial results showed that for patients previously treated with alectinib, the confirmed overall response rate was 49%, with a duration of response lasting six months or longer in 76% of responders. For those who had received two or more prior ALK TKIs and chemotherapy, the overall response rate was 32%.

Impact

This approval is expected to have a considerable impact on patients suffering from ALK-positive NSCLC, a demographic that often faces limited treatment options. The new drug aims to provide these patients with a more effective and tolerable treatment alternative, addressing the unmet needs in this challenging area of oncology.

What's Next

The filing does not specify what happens next, but it indicates that Nelkarmi is also being evaluated in an ongoing phase III trial, ALKAZAR, targeting TKI-naïve ALK-positive NSCLC patients. This suggests that GSK is committed to further developing its oncology portfolio and expanding treatment options for this patient population.

Source: SEC filing accession number 0001654954-26-009959.